Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Liver Transpl. 2016 May;22(5):627–634. doi: 10.1002/lt.24395

Figure 1. Overall survival and cumulative incidence of hepatocellular carcinoma recurrence among sirolimus users and non-users.

Figure 1

The upper curves depict the overall survival probability across time after 3 months post-transplant for sirolimus users and non-users. The lower curves depict the cumulative incidence of HCC recurrence after accounting for the competing risk of death.

SRL=sirolimus